Loading…
Lobbying Spend
—
Filings
3
Firms Hired
1
Active Period
2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Biosimilars Access and Affordability Act
2026 · third_quarter · Firm: AVENUE SOLUTIONS
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 10628
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · third_quarter · Firm: AVENUE SOLUTIONS
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Biosimilar Red Tape Elimination Act
2026 · third_quarter · Firm: AVENUE SOLUTIONS
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5526
Chinese Military and Surveillance Company Sanctions Act of 2024
2026 · third_quarter · Firm: AVENUE SOLUTIONS
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: — · Firm income: $50,000
Matched citations: S. 5571
Biosimilar Red Tape Elimination Act
2026 · third_quarter · Firm: AVENUE SOLUTIONS
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: — · Firm income: $50,000
Matched citations: S. 1954
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related To S. 5459, The Biosimilar Access and Affordability Act; Issues related to Senate Finance Dear Colleague process
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Biosimilar Red Tape Elimination Act
2026 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related To S. 5459, The Biosimilar Access and Affordability Act; Issues related to Senate Finance Dear Colleague process
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5526
Biosimilars Access and Affordability Act
2026 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related To S. 5459, The Biosimilar Access and Affordability Act; Issues related to Senate Finance Dear Colleague process
Client expense: — · Firm income: $50,000
Matched citations: S. 5459
Biosimilar Red Tape Elimination Act
2026 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related To S. 5459, The Biosimilar Access and Affordability Act; Issues related to Senate Finance Dear Colleague process
Client expense: — · Firm income: $50,000
Matched citations: S. 1954
Source: Senate LDA